Glaukos Corp
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. The company offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathw… Read more
Glaukos Corp (GKOS) - Total Assets
Latest total assets as of September 2025: $999.38 Million USD
Based on the latest financial reports, Glaukos Corp (GKOS) holds total assets worth $999.38 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Glaukos Corp - Total Assets Trend (2012–2024)
This chart illustrates how Glaukos Corp’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Glaukos Corp - Asset Composition Analysis
Current Asset Composition (December 2024)
Glaukos Corp's total assets of $999.38 Million consist of 46.1% current assets and 53.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 17.4% |
| Accounts Receivable | $60.74 Million | 6.2% |
| Inventory | $57.68 Million | 5.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $263.44 Million | 27.0% |
| Goodwill | $66.13 Million | 6.8% |
Asset Composition Trend (2012–2024)
This chart illustrates how Glaukos Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Glaukos Corp's current assets represent 46.1% of total assets in 2024, a decrease from 68.2% in 2012.
- Cash Position: Cash and equivalents constituted 17.4% of total assets in 2024, down from 33.5% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 33.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 27.0% of total assets.
Glaukos Corp Competitors by Total Assets
Key competitors of Glaukos Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
Glaukos Corp - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Glaukos Corp generates 0.39x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Glaukos Corp is currently not profitable relative to its asset base.
Glaukos Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.20 | 5.54 | 9.45 |
| Quick Ratio | 4.47 | 4.71 | 9.13 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $367.25 Million | $ 325.60 Million | $ 419.74 Million |
Glaukos Corp - Advanced Valuation Insights
This section examines the relationship between Glaukos Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.14 |
| Latest Market Cap to Assets Ratio | 5.86 |
| Asset Growth Rate (YoY) | 3.7% |
| Total Assets | $974.76 Million |
| Market Capitalization | $5.71 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Glaukos Corp's assets at a significant premium ( 5.86x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Glaukos Corp's assets grew by 3.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Glaukos Corp (2012–2024)
The table below shows the annual total assets of Glaukos Corp from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $974.76 Million | +3.65% |
| 2023-12-31 | $940.41 Million | -12.45% |
| 2022-12-31 | $1.07 Billion | -4.84% |
| 2021-12-31 | $1.13 Billion | +12.27% |
| 2020-12-31 | $1.01 Billion | +22.86% |
| 2019-12-31 | $818.40 Million | +295.42% |
| 2018-12-31 | $206.97 Million | +24.80% |
| 2017-12-31 | $165.84 Million | +23.42% |
| 2016-12-31 | $134.37 Million | +15.18% |
| 2015-12-31 | $116.66 Million | +348.33% |
| 2014-12-31 | $26.02 Million | -15.73% |
| 2013-12-31 | $30.88 Million | +497.81% |
| 2012-12-31 | $5.17 Million | -- |